Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Change in Account Payables (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Change in Account Payables readings, the most recent being $1.8 million for Q1 2026.

  • Quarterly Change in Account Payables rose 220.63% to $1.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Mar 2026, up 125.79% year-over-year, with the annual reading at $535000.0 for FY2025, 3721.43% up from the prior year.
  • Change in Account Payables hit $1.8 million in Q1 2026 for DiaMedica Therapeutics, up from -$445000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.8 million in Q1 2026 and bottomed at -$924000.0 in Q2 2023.
  • Average Change in Account Payables over 5 years is $163764.7, with a median of $43000.0 recorded in 2024.
  • The largest annual shift saw Change in Account Payables surged 5785.71% in 2024 before it plummeted 672.09% in 2025.
  • DiaMedica Therapeutics' Change in Account Payables stood at -$130000.0 in 2022, then surged by 148.46% to $63000.0 in 2023, then crashed by 466.67% to -$231000.0 in 2024, then plummeted by 92.64% to -$445000.0 in 2025, then soared by 508.54% to $1.8 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Change in Account Payables are $1.8 million (Q1 2026), -$445000.0 (Q4 2025), and $659000.0 (Q3 2025).